Treatment Development and Delivery Program

eagle-i ID

Resource Type

Properties

1. Resource Description

   Program Goals Despite the fact that cigarette smoking continues to be the greatest preventable cause of morbidity and mortality, there are currently only three FDA-approved medications for nicotine dependence: nicotine replacement therapy (NRT; transdermal nicotine (TN), nasal spray, gum, lozenge), bupropion, and varenicline. Although these treatments are effective for some smokers, nearly 75% relapse within a year. There is a clear need to identify novel treatment approaches to help more smokers quit. The Treatment Development and Delivery Program within CIRNA is guided by the following goals: (1) to develop and evaluate novel behavioral and pharmacological interventions for nicotine dependence; (2) to develop novel methods to improve the efficacy and effectiveness of FDA-approved treatment for nicotine dependence; (3) to expand the use of treatments for nicotine dependence to under-served populations.

2. Contact

   Schnoll, Robert., PhD

3. Affiliation

   Center for Interdisciplinary Research on Nicotine Addiction

4. Website(s)

   https://www.med.upenn.edu/cirna/treatment-development-and-delivery.html

5. Other members

   Lerman, Caryn., PhD

6. Other members

   Audrain-McGovern, Janet., PhD